A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

What this study is about

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.

Who can join (things the study team will check)

✅ You may be able to join if…

• Has undergone margin negative, completely resected non-small cell lung cancer (NSCLC), and has pathological Stage II, IIIA, IIIB (N2) squamous or nonsquamous tumor, node, metastasis (TNM) staging per American Joint Committee on Cancer (AJCC) Eighth Edition guidelines.
• Has no evidence of disease before randomization.
• Has received at least one dose of adjuvant treatment with standard of care platinum doublet chemotherapy.
• No more than 24 weeks have elapsed between surgical resection of curative intent and the first dose of pembrolizumab.
• Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.
• Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
• Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).

🚫 You may not be able to join if…

• Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large cell components or a sarcomatoid carcinoma.
• HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• Received prior neoadjuvant therapy for their current NSCLC diagnosis.
• Received or is a candidate to receive radiotherapy for their current NSCLC diagnosis.
• Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-PD-ligand 1 (L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
• Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
• Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
• Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
• Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
• Known additional malignancy that is progressing or has required active treatment within the past 5 years.
• Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed.
• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
• Active infection requiring systemic therapy.

Where this trial is running

• Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska, United States
• The University of Arizona Cancer Center - North Campus ( Site 0071), Tucson, Arizona, United States
• YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020), Yuma, Arizona, United States
• UCLA Clinical & Translational Research Center (CTRC) ( Site 0059), Los Angeles, California, United States
• Hoag Memorial Hospital Presbyterian ( Site 4042), Newport Beach, California, United States
• Hoag Memorial Hospital Presbyterian ( Site 4048), Newport Beach, California, United States
• St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074), Orange, California, United States
• University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030), Orange, California, United States
• UCHealth Memorial Hospital-Heme Onc ( Site 0052), Colorado Springs, Colorado, United States
• George Washington University Medical Faculty Associates ( Site 4064), Washington D.C., District of Columbia, United States
• Mayo Clinic Florida ( Site 4043), Jacksonville, Florida, United States
• Miami Cancer Institute at Baptist Health, Inc. ( Site 4047), Miami, Florida, United States

+ 217 more sites.

Who to contact

Toll Free Number · 1-888-577-8839 · Trialsites@msd.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06077760.